ORIENT-31 is a randomized, double-blind, multicenter, phase III trial evaluating the combination of sintilimab, a PD-1 inhibitor, with the bevacizumab biosimilar IBI305, and chemotherapy in patients with EGFR-mutant non-squamous NSCLC who have progressed after EGFR-TKI therapy. Here, EGFR is linked to non-small cell lung carcinoma.